The University of Chicago Header Logo

Connection

Arlene Chapman to Disease Progression

Back to Details
This is a "connection" page, showing publications Arlene Chapman has written about Disease Progression.
Arlene Chapman
Connection Strength
2.187
Disease Progression
  1. Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort. BMC Nephrol. 2018 12 27; 19(1):378.
    View in: PubMed
    Score: 0.121
  2. Hypoxia-Inducible Factor 1a (HIF-1a), Angiopoietin-2 (ANG-2) and Endocan: Novel Biomarkers of Disease Progression Involving Polycystic Kidney Disease. Am J Nephrol. 2018; 47(4):228-230.
    View in: PubMed
    Score: 0.115
  3. Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials. Am J Kidney Dis. 2018 05; 71(5):666-676.
    View in: PubMed
    Score: 0.113
  4. ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing. Am J Kidney Dis. 2018 02; 71(2):294-296.
    View in: PubMed
    Score: 0.113
  5. New treatment paradigms for ADPKD: moving towards precision medicine. Nat Rev Nephrol. 2017 Dec; 13(12):750-768.
    View in: PubMed
    Score: 0.111
  6. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015 Jul; 88(1):17-27.
    View in: PubMed
    Score: 0.093
  7. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012 Mar; 7(3):479-86.
    View in: PubMed
    Score: 0.075
  8. Imaging approaches to patients with polycystic kidney disease. Semin Nephrol. 2011 May; 31(3):237-44.
    View in: PubMed
    Score: 0.071
  9. The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol. 2010 Jan; 5(1):102-9.
    View in: PubMed
    Score: 0.065
  10. Polycystic kidney disease: The cadence of kidney growth in ADPKD. Nat Rev Nephrol. 2009 Jun; 5(6):311-2.
    View in: PubMed
    Score: 0.062
  11. Renal volume in children with ADPKD: size matters. Clin J Am Soc Nephrol. 2009 Apr; 4(4):698-9.
    View in: PubMed
    Score: 0.062
  12. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol. 2008 Jul; 3(4):1197-204.
    View in: PubMed
    Score: 0.059
  13. Treatment of autosomal dominant polycystic kidney disease (ADPKD): the new horizon for children with ADPKD. Pediatr Nephrol. 2008 Jul; 23(7):1029-36.
    View in: PubMed
    Score: 0.057
  14. Autosomal dominant polycystic kidney disease: time for a change? J Am Soc Nephrol. 2007 May; 18(5):1399-407.
    View in: PubMed
    Score: 0.054
  15. Utility of new image-derived biomarkers for autosomal dominant polycystic kidney disease prognosis using automated instance cyst segmentation. Kidney Int. 2023 08; 104(2):334-342.
    View in: PubMed
    Score: 0.040
  16. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial. Am J Kidney Dis. 2023 05; 81(5):517-527.e1.
    View in: PubMed
    Score: 0.040
  17. Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2022 03; 17(3):374-384.
    View in: PubMed
    Score: 0.038
  18. The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. JCI Insight. 2020 08 06; 5(15).
    View in: PubMed
    Score: 0.034
  19. Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. Am J Kidney Dis. 2021 02; 77(2):255-263.
    View in: PubMed
    Score: 0.034
  20. Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2020 07; 31(7):1640-1651.
    View in: PubMed
    Score: 0.033
  21. Growth Pattern of Kidney Cyst Number and Volume in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2019 06 07; 14(6):823-833.
    View in: PubMed
    Score: 0.031
  22. Identifying patient-important outcomes in polycystic kidney disease: An international nominal group technique study. Nephrology (Carlton). 2019 Dec; 24(12):1214-1224.
    View in: PubMed
    Score: 0.031
  23. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney Int. 2019 07; 96(1):159-169.
    View in: PubMed
    Score: 0.031
  24. Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease. Kidney Int. 2019 05; 95(5):1253-1261.
    View in: PubMed
    Score: 0.031
  25. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course. BMC Nephrol. 2019 02 25; 20(1):66.
    View in: PubMed
    Score: 0.031
  26. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J Am Soc Nephrol. 2018 10; 29(10):2458-2470.
    View in: PubMed
    Score: 0.030
  27. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrol Dial Transplant. 2018 04 01; 33(4):645-652.
    View in: PubMed
    Score: 0.029
  28. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade? Curr Hypertens Rev. 2018; 14(1):39-47.
    View in: PubMed
    Score: 0.028
  29. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int. 2018 03; 93(3):691-699.
    View in: PubMed
    Score: 0.028
  30. Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2018 02; 29(2):571-578.
    View in: PubMed
    Score: 0.028
  31. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial Transplant. 2017 Nov 01; 32(11):1857-1865.
    View in: PubMed
    Score: 0.028
  32. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2017 Sep 07; 12(9):1461-1469.
    View in: PubMed
    Score: 0.027
  33. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2017 11; 92(5):1206-1216.
    View in: PubMed
    Score: 0.027
  34. Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression. Nephrol Dial Transplant. 2017 03 01; 32(3):487-497.
    View in: PubMed
    Score: 0.027
  35. Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials. Curr Hypertens Rev. 2017; 13(2):109-120.
    View in: PubMed
    Score: 0.026
  36. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int. 2017 02; 91(2):493-500.
    View in: PubMed
    Score: 0.026
  37. Automated segmentation of liver and liver cysts from bounded abdominal MR images in patients with autosomal dominant polycystic kidney disease. Phys Med Biol. 2016 11 21; 61(22):7864-7880.
    View in: PubMed
    Score: 0.026
  38. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. Clin J Am Soc Nephrol. 2016 05 06; 11(5):803-811.
    View in: PubMed
    Score: 0.025
  39. Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC). Am J Kidney Dis. 2015 Oct; 66(4):583-90.
    View in: PubMed
    Score: 0.024
  40. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11; 371(24):2267-76.
    View in: PubMed
    Score: 0.023
  41. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11; 371(24):2255-66.
    View in: PubMed
    Score: 0.023
  42. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015 Jan; 26(1):160-72.
    View in: PubMed
    Score: 0.022
  43. Novel methodology to evaluate renal cysts in polycystic kidney disease. Am J Nephrol. 2014; 39(3):210-7.
    View in: PubMed
    Score: 0.022
  44. Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2013 Jul; 8(7):1089-97.
    View in: PubMed
    Score: 0.020
  45. Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int. 2012 Apr; 81(8):784-90.
    View in: PubMed
    Score: 0.019
  46. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int. 2012 Mar; 81(6):577-85.
    View in: PubMed
    Score: 0.019
  47. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol. 2011 Oct; 6(10):2499-507.
    View in: PubMed
    Score: 0.018
  48. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011 Mar; 6(3):640-7.
    View in: PubMed
    Score: 0.017
  49. Renal CD14 expression correlates with the progression of cystic kidney disease. Kidney Int. 2010 Sep; 78(6):550-60.
    View in: PubMed
    Score: 0.017
  50. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2007 Jan; 2(1):112-20.
    View in: PubMed
    Score: 0.013
  51. Volume progression in polycystic kidney disease. N Engl J Med. 2006 May 18; 354(20):2122-30.
    View in: PubMed
    Score: 0.013
  52. Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort. J Am Soc Nephrol. 2006 Mar; 17(3):854-62.
    View in: PubMed
    Score: 0.012
  53. Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP). Am J Kidney Dis. 2005 Dec; 46(6):1058-64.
    View in: PubMed
    Score: 0.012
  54. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol. 2006 Jan; 1(1):148-57.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.